Startup entity
acquisition is the sole category represented across all 1 tracked stories. Keytruda is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window.
Last mentioned: 2d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. Keytruda is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. The 8 average consequence score is above the beat benchmark of 6.6 in the same window. We currently track 1 Startup story that mention Terns Pharmaceuticals, all published on March 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 46 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Terns Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion, securing a late-stage leukemia candidate to diversify its oncology portfolio. The deal provides Merck with TERN-701, a promising treatment for chronic myeloid leukemia, as it prepares for the 2028 patent expiration of its blockbuster drug Keytruda.
Terns Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
